Zoetis Inc. (NYSE: ZTS) Stock Competitors & Peer Comparison
See ZTS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZTS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZTS | $77.60 | +1.20% | 31.5B | 11.40 | $6.58 | +2.78% |
| LLY | $1,263.89 | -1.29% | 1.2T | 39.56 | $31.49 | +0.53% |
| JNJ | $271.59 | -0.67% | 645.3B | 24.96 | $10.73 | +1.95% |
| ABBV | $265.67 | -0.11% | 462.6B | 25.69 | $10.19 | +2.60% |
| MRK | $152.10 | -0.07% | 368.5B | 46.48 | $3.21 | +2.23% |
| NVS | $159.14 | -0.73% | 297B | 17.98 | $8.69 | +3.03% |
| AZN | $166.10 | +0.70% | 255.2B | 17.77 | $9.26 | +1.27% |
| AMGN | $438.62 | -0.85% | 234.1B | 19.39 | $22.37 | +2.26% |
| NVO | $46.96 | +1.02% | 205.1B | 11.49 | $4.02 | +2.51% |
| GILD | $147.47 | -0.09% | 178.1B | -367.79 | -$0.39 | +2.22% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
ZTS vs LLY Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while LLY trades at $1,263.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas LLY's P/E ratio is 39.56. In terms of profitability, ZTS's ROE is +0.69%, compared to LLY's ROE of +0.93%. Regarding short-term risk, ZTS is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
ZTS vs JNJ Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, JNJ has a market cap of 645.3B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while JNJ trades at $271.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas JNJ's P/E ratio is 24.96. In terms of profitability, ZTS's ROE is +0.69%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, ZTS is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
ZTS vs ABBV Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, ABBV has a market cap of 462.6B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while ABBV trades at $265.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas ABBV's P/E ratio is 25.69. In terms of profitability, ZTS's ROE is +0.69%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, ZTS is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
ZTS vs MRK Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, MRK has a market cap of 368.5B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while MRK trades at $152.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas MRK's P/E ratio is 46.48. In terms of profitability, ZTS's ROE is +0.69%, compared to MRK's ROE of +0.07%. Regarding short-term risk, ZTS is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check MRK's competition here
Novartis AG (NYSE: NVS)
ZTS vs NVS Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, NVS has a market cap of 297B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while NVS trades at $159.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas NVS's P/E ratio is 17.98. In terms of profitability, ZTS's ROE is +0.69%, compared to NVS's ROE of +0.30%. Regarding short-term risk, ZTS is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
ZTS vs AZN Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, AZN has a market cap of 255.2B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while AZN trades at $166.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas AZN's P/E ratio is 17.77. In terms of profitability, ZTS's ROE is +0.69%, compared to AZN's ROE of +0.22%. Regarding short-term risk, ZTS is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
ZTS vs AMGN Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, AMGN has a market cap of 234.1B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while AMGN trades at $438.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas AMGN's P/E ratio is 19.39. In terms of profitability, ZTS's ROE is +0.69%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, ZTS is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
ZTS vs NVO Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, NVO has a market cap of 205.1B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while NVO trades at $46.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas NVO's P/E ratio is 11.49. In terms of profitability, ZTS's ROE is +0.69%, compared to NVO's ROE of +0.59%. Regarding short-term risk, ZTS is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
ZTS vs GILD Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, GILD has a market cap of 178.1B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while GILD trades at $147.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas GILD's P/E ratio is -367.79. In terms of profitability, ZTS's ROE is +0.69%, compared to GILD's ROE of -0.16%. Regarding short-term risk, ZTS is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
ZTS vs PFE Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, PFE has a market cap of 158.5B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while PFE trades at $28.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas PFE's P/E ratio is 9.12. In terms of profitability, ZTS's ROE is +0.69%, compared to PFE's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
ZTS vs BMY Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, BMY has a market cap of 133.8B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while BMY trades at $67.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas BMY's P/E ratio is 11.04. In terms of profitability, ZTS's ROE is +0.69%, compared to BMY's ROE of +0.47%. Regarding short-term risk, ZTS is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check BMY's competition here
Sanofi (NASDAQ: SNY)
ZTS vs SNY Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, SNY has a market cap of 108.4B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while SNY trades at $45.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas SNY's P/E ratio is 9.84. In terms of profitability, ZTS's ROE is +0.69%, compared to SNY's ROE of +0.06%. Regarding short-term risk, ZTS is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SNY's competition here
GSK plc (NYSE: GSK)
ZTS vs GSK Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, GSK has a market cap of 104.1B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while GSK trades at $52.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas GSK's P/E ratio is 11.22. In terms of profitability, ZTS's ROE is +0.69%, compared to GSK's ROE of +0.24%. Regarding short-term risk, ZTS is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
ZTS vs BIIB Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, BIIB has a market cap of 31.7B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while BIIB trades at $217.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas BIIB's P/E ratio is 13.53. In terms of profitability, ZTS's ROE is +0.69%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
ZTS vs HZNP Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas HZNP's P/E ratio is 61.86. In terms of profitability, ZTS's ROE is +0.69%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, ZTS is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
ZTS vs GRFS Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while GRFS trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas GRFS's P/E ratio is 9.18. In terms of profitability, ZTS's ROE is +0.69%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, ZTS is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
ZTS vs OGN Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while OGN trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas OGN's P/E ratio is 4.10. In terms of profitability, ZTS's ROE is +0.69%, compared to OGN's ROE of +0.23%. Regarding short-term risk, ZTS is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
ZTS vs CELG-RI Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while CELG-RI trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.69%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, ZTS is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
ZTS vs CTOR Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while CTOR trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas CTOR's P/E ratio is -1.62. In terms of profitability, ZTS's ROE is +0.69%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, ZTS is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
ZTS vs SCLX Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, SCLX has a market cap of 49.2M. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while SCLX trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas SCLX's P/E ratio is -0.15. In terms of profitability, ZTS's ROE is +0.69%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, ZTS is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
ZTS vs SCLXW Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas SCLXW's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.69%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, ZTS is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
ZTS vs MIRA Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, MIRA has a market cap of 29.8M. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while MIRA trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas MIRA's P/E ratio is -0.49. In terms of profitability, ZTS's ROE is +0.69%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, ZTS is more volatile compared to MIRA. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
ZTS vs BDSIW Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, ZTS's ROE is +0.69%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, ZTS is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
ZTS vs CRXT Comparison August 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 31.5B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, ZTS is priced at $77.60 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.40, whereas CRXT's P/E ratio is -0.02. In terms of profitability, ZTS's ROE is +0.69%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, ZTS is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CRXT's competition here